These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 8624188)

  • 1. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder.
    Arnsten AF; Steere JC; Hunt RD
    Arch Gen Psychiatry; 1996 May; 53(5):448-55. PubMed ID: 8624188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Roles of alpha-2 adrenoceptor in prefrontal cortical cognitive functions].
    Mao ZM; Li BM; Arnsten AF
    Sheng Li Ke Xue Jin Zhan; 1999 Jan; 30(1):17-22. PubMed ID: 12532843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
    Arnsten AF; Scahill L; Findling RL
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):393-406. PubMed ID: 17822336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder.
    Scahill L; Barloon L; Farkas L
    J Child Adolesc Psychiatr Nurs; 1999; 12(4):168-73. PubMed ID: 10876518
    [No Abstract]   [Full Text] [Related]  

  • 5. Noradrenergic influences on prefrontal cortical cognitive function: opposing actions at postjunctional alpha 1 versus alpha 2-adrenergic receptors.
    Arnsten AF; Steere JC; Jentsch DJ; Li BM
    Adv Pharmacol; 1998; 42():764-7. PubMed ID: 9328010
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.
    Coull JT
    Drugs Aging; 1994 Aug; 5(2):116-26. PubMed ID: 7981483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamine influences on dorsolateral prefrontal cortical networks.
    Arnsten AF
    Biol Psychiatry; 2011 Jun; 69(12):e89-99. PubMed ID: 21489408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability.
    Lapiz MD; Morilak DA
    Neuroscience; 2006 Feb; 137(3):1039-49. PubMed ID: 16298081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the locus coeruleus in the control of paradoxical sleep generation in the cat.
    Sakai K; Crochet S
    Arch Ital Biol; 2004 Jul; 142(4):421-7. PubMed ID: 15493546
    [No Abstract]   [Full Text] [Related]  

  • 11. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
    Arnsten AF; Pliszka SR
    Pharmacol Biochem Behav; 2011 Aug; 99(2):211-6. PubMed ID: 21295057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat.
    Ji XH; Ji JZ; Zhang H; Li BM
    Neuropsychopharmacology; 2008 Aug; 33(9):2263-71. PubMed ID: 17957212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.
    Arnsten AFT
    Neurobiol Learn Mem; 2020 Dec; 176():107327. PubMed ID: 33075480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential noradrenergic targets for cognitive enhancement in schizophrenia.
    Friedman JI; Stewart DG; Gorman JM
    CNS Spectr; 2004 May; 9(5):350-5. PubMed ID: 15115947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locus coeruleus and regulation of behavioral flexibility and attention.
    Aston-Jones G; Rajkowski J; Cohen J
    Prog Brain Res; 2000; 126():165-82. PubMed ID: 11105646
    [No Abstract]   [Full Text] [Related]  

  • 16. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys.
    Steere JC; Arnsten AF
    Behav Neurosci; 1997 Oct; 111(5):883-91. PubMed ID: 9383511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions.
    Fukuyama K; Nakano T; Shiroyama T; Okada M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats.
    Birnbaum SG; Podell DM; Arnsten AF
    Pharmacol Biochem Behav; 2000 Nov; 67(3):397-403. PubMed ID: 11164065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine vs noradrenaline: inverted-U effects and ADHD theories.
    Levy F
    Aust N Z J Psychiatry; 2009 Feb; 43(2):101-8. PubMed ID: 19153917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex.
    Okada M; Fukuyama K; Kawano Y; Shiroyama T; Suzuki D; Ueda Y
    Neuropharmacology; 2019 Sep; 156():107547. PubMed ID: 30802458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.